Tag: Cancer: Ovarian
BRCA Mutation Testing Shifts to Unaffected Women
From 2004 to 2014, greater percent of testing in unaffected women versus cancer patients
FDA Approves Zejula for Certain Female Cancers
PARP inhibitor may help fight tumors affecting the ovaries, fallopian tubes, or peritoneum
Hormonal Maintenance Tx Ups PFS in Low-Grade Serous Cancer
Significantly longer progression-free survival in low-grade serous carcinoma of the ovary or peritoneum
Coffee Speeds Time to Bowel Movement After Gynecologic Sx
Findings for patients after complete staging surgery
Laparoscopy Can Prevent Futile Primary Cytoreductive Surgery
Findings in women with suspected advanced-stage ovarian cancer
FDA Grants Fast-Track Approval to Ovarian Cancer Drug
Rubraca's use is specific to women with deleterious BRCA mutations
Mutations Identified in Uterine, Ovarian Carcinosarcomas
Mutations in previously ID'd cancer genes; excess of mutations in genes encoding histone H2A, H2B
Neoadjuvant Chemotherapy Use Up in Ovarian Cancer Treatment
NACT use up from 2003 to 2012; linked to shorter overall survival in stage IIIC but not stage IV disease
Oral Contraceptives May Be Cause of Drop in Ovarian CA Mortality
Rates down 16 percent in U.S., 8 percent in Canada, and 10 percent in Europe over a decade
Recs Developed for Neoadjuvant Chemo in Ovarian Cancer
Guidance provided for clinicians treating women with stage IIIC or IV epithelial ovarian cancer
